Biosimilar debate heats up at BIO
Speakers at the 2008 BIO International Convention in San Diego yesterday discussed the regulatory and scientific issues created by generic biological drugs, commonly known as biosimilars or follow-on biologics
Biosimilars are products that attempt to replicate biologics medicines which involve living organisms and are similar, but not identical to, the innovator drug. Like their pharmaceutical counterparts, they are offered at discounted prices to patients.
But because biosimilars...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.